Nicolas Feltes Benitez

Dr. Nicolas Feltes Benitez

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2024 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
JLJoan Lozano
Joan Lozano
CFCarlos G. Forero
Carlos G. Forero
MTMontserrat Colomer i Truyols
Montserrat Colomer i Truyols
SRSaturio Paredes Rubio
Saturio Paredes Rubio
EJEsther Jovell-Fernandez
Esther Jovell-Fernandez

7 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
FCFelipe Counago
Felipe Counago
SRSaturio Paredes Rubio
Saturio Paredes Rubio
MGManuel Galdeano-Rubio
Manuel Galdeano-Rubio
EJEsther Jovell-Fernandez
Esther Jovell-Fernandez
Background: Biochemical recurrence (BCR) after definitive radiotherapy (RT) in localized prostate cancer (PC) is a clinically relevant event that impacts long-term management and prognosis. However, the prognostic value of certain biopsy-derived pathological parameters remains underexplored in RT-treated cohorts. Methods: We retrospectively analyzed 444 patients with localized PC treated with external beam radiotherapy (with or without androgen deprivation therapy) between 2013 and 2019. Clinical, radiological, and detailed histopathological data, including Gleason score, perineural invasion, and the number and proportion of positive biopsy cores—were collected. Logistic regression models were used to identify predictors of BCR. Results: After a median follow-up of 72 months, 11.7% of patients developed BCR. In multivariable analysis, higher PSA at diagnosis (p = 0.05), higher Gleason score (ISUP ≥ 4; p = 0.036), and greater tumor burden in biopsy cores—quantified as both the number and proportion of positive cores per lobe and overall (p < 0.05)—were independently associated with BCR. Perineural invasion showed a univariable association (p = 0.036), though it did not remain significant after adjustment. Overall, 19.2% (10/52) of recurrences were diagnosed beyond five years post-treatment, underscoring the need for prolonged follow-up. Conclusions: PSA at diagnosis, the extent of tumor involvement in diagnostic biopsies, and ISUP grade group ≥ 4 (Gleason score ≥ 8) were identified as independent predictors of biochemical recurrence after RT in localized prostate cancer. Lower Gleason categories and perineural invasion showed only a trend toward significance in the multivariable analysis, suggesting that their predictive effect may be attenuated by other covariates.

26 March 2026 in Life
Verified
Journal Article
Open access
PDF file
MTMacarena Teja
Macarena Teja
MBMiguel Angel Angel Berenguer Berenguer
Miguel Angel Angel Berenguer Berenguer
FLFernando López-Campos
Fernando López-Campos
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
ASAlexandra Stoica
Alexandra Stoica
FCFelipe Counago
Felipe Counago
Oligometastatic prostate cancer represents a distinct biological state between localized and widely metastatic disease, characterized by a limited number of lesions. Stereotactic body radiotherapy (SBRT) has emerged as a key metastasis-directed therapy (MDT), enabling precise ablation of metastatic lesions with minimal toxicity. Prospective clinical trials such as SABR-COMET, STOMP, ORIOLE, RADIOSA, and EXTEND have shown that SBRT delays disease progression, prolongs progression-free survival, and postpones the need for systemic therapy, while maintaining a favorable safety profile. Nevertheless, methodological limitations persist, including heterogeneity in defining oligometastatic disease, variability in dosing and fractionation, and the lack of predictive biomarkers. Ongoing phase III trials aim to validate the integration of SBRT with modern systemic therapies, including next-generation androgen receptor pathway inhibitors, to optimize clinical outcomes in hormone-sensitive and castration-resistant oligometastatic prostate cancer. This review summarizes current evidence, clinical applications, and future directions for SBRT in this patient population.

25 December 2025 in Life
Verified
Journal Article
Open access
PDF file
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
MGManuel Galdeano-Rubio
Manuel Galdeano-Rubio
JMJesus Muñoz-Rodriguez
Jesus Muñoz-Rodriguez
ADArturo Domínguez
Arturo Domínguez
JMJosep Maria Solé i Monné
Josep Maria Solé i Monné
SRSaturio Paredes Rubio
Saturio Paredes Rubio
Introduction: ADT is routinely combined with radiotherapy (RT) for intermediate- and high-risk prostate cancer. While prostate shrinkage may facilitate planning, prospective CT-based, patient-level estimates over short, workflow-relevant intervals are scarce. Methods: We conducted a prospective study of 47 patients starting luteinizing hormone-releasing hormone agonist (LHRHa) therapy (leuprolide, 6-month depot). Prostate volumes were independently contoured by three blinded radiation oncologists on paired CT scans at baseline and ~8 weeks post-injection. The primary outcomes were the mean relative volume change and the proportion achieving a clinically relevant reduction (≥15%). PSA and testosterone were recorded at both time points; correlations and exploratory univariable logistic regression for ≥15% reduction were performed at the patient level. Results: Mean relative volume reduction ranged from −18.5% to −21.3% across observers; ≥60% of patients met the ≥15% threshold (RT-A 61.7%, RT-B 66.0%, RT-C 74.5%). PSA and testosterone decreased substantially (e.g., median PSA from 9.64 to 1.84 nmol/L) and were moderately correlated (Spearman ρ = 0.43, p = 0.002; Pearson r = 0.51, p < 0.001). No baseline clinical, histologic, or biochemical variables reached statistical significance for predicting ≥15% volume reduction; % PSA change showed a non-significant trend (OR 1.03; 95% CI 1.00–1.07; p = 0.076). Conclusions: Short-course LHRHa induced consistent CT-measured cytoreduction, with more than half of cases achieving ≥15% shrinkage within 8 weeks. Prostate downsizing was reproducible across readers and accompanied by marked PSA and testosterone declines, although biochemical responses did not predict volumetric change. These findings support incorporating a short neoadjuvant “window” before RT simulation and highlight the need for larger studies to refine predictors and compare agonist vs. antagonist trajectories.

16 March 2026 in Actas Urológicas Españolas (English Edition)
Verified
Journal Article
Closed access
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
FCF. Couñago
F. Couñago
SPS. Paredes-Rubio
S. Paredes-Rubio
PHP. Peleteiro Higuero
P. Peleteiro Higuero
JOJ.G. Molina Osorio
J.G. Molina Osorio
EPE. González del Portillo
E. González del Portillo

26 February 2026 in Actas Urológicas Españolas
Verified
Journal Article
Closed access
Nicolas Feltes BenitezNicolas Feltes Benitez
Nicolas Feltes Benitez
FCF. Couñago
F. Couñago
SPS. Paredes-Rubio
S. Paredes-Rubio
PHP. Peleteiro Higuero
P. Peleteiro Higuero
JOJ.G. Molina Osorio
J.G. Molina Osorio
EPE. González del Portillo
E. González del Portillo